Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2803)	1/7/2005 5:03:03 AM
From: Savant	Respond to of 3576

Yes, both appear to be targeting the same prospects. As for xenotransplantation, I would prefer that there be LONG and CONTINUOUS testing, prior to human use. Jumping bean virus--that concerns me. Perhaps this might be a bit safer: "Revivicor will use the nuclear transfer technology to produce fully-human polyclonal antibodies in the blood of genetically modified pigs. These antibodies may be used for the treatment of infectious agents, including antibiotic resistant bacteria, viruses, potential biowarfare pathogens, and for clearance of toxins." Thoughts? Best, Savant